Advertisement

Femoral Lesion Change in Relation to Measured Risk Factors in the Stockholm-Uppsala Trial

  • Anders G. Olsson
  • Uno Erikson
  • Gunnar Helmius
  • Anders Hemmingsson
  • Ingar Holme
  • Gunnar Ruhn
Conference paper

Abstract

Our access to highly efficient drugs against hyperlipoproteinemia (1,2) and to a high resolution femoral angiography technique (3) prompted us to study the effect of pronounced serum-lipid lowering on the development of femoral atherosclerosis in hyperlipoproteinemia.

Keywords

Peripheral Artery Disease Serum Lipoprotein Measure Risk Factor Computer Assisted Image Ischemic Vascular Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Olsson AG, Walldius G, Wahlberg G (1986) Pharmacological control of hyperlipidaemia: Nicotinic acid and its analogues — mechanisms of action, effects and clinical usage. In: Fears R (ed) Pharmacological Control of Hyperlipidaemia. J Prous Science Publishers, pp. 217–230.Google Scholar
  2. 2.
    Rössner S, Olsson AG (1980) Effects of combined procetofene-nicotinic acid therapy in treatment of hypertriglyceridaemia. Atherosclerosis 35:413–417.PubMedCrossRefGoogle Scholar
  3. 3.
    Ruhn G, Erikson U, Helmius G, Hemmingsson A (1982) Computerized quantitation of atherosclerosis in an experimental model. Acta Radiol (Diagn) 23:621–625.Google Scholar
  4. 4.
    Olsson AG, Erikson U, Helmius G, Hemmingsson A, Ruhn G (1984) Regression of femoral atherosclerosis in humans: Methodological and clinical problems associated with studies on femoral atherosclerosis development as assessed by angiograms. In: Manilow MR, Blaton VH (eds) Regression of Atherosclerotic Lesions: Experimental Studies and Observations in Humans. New York: Plenum Press, pp. 311–328.Google Scholar
  5. 5.
    Erikson U, Helmius G, Hemmingsson A, Olsson AG, Ruhn G Arteriography of patients included in a regression study. Workshop on the Evolution of the Human Atherosclerotic Plaque. Rockville, Maryland, September 1986.Google Scholar
  6. 6.
    Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS, Strasser T (1970) Classification of hyperlipidaemias and hyperlipoproteinaemias. Bull WHO 43:891.PubMedGoogle Scholar
  7. 7.
    Carlson K (1973) Lipoprotein fractionation. J Clin Path 26 Suppl (Ass Clin Path) 5:32–37.Google Scholar
  8. 8.
    Zlatkis A, Zak B, Boyle AJ (1953) A new method for the direct determination of serum cholesterol. J Lab Clin Med 41:486–492.PubMedGoogle Scholar
  9. 9.
    Fletcher MJ (1968) A colorimetric method for estimating serum triglycerides. Clin Chim Acta 22:393–397.PubMedCrossRefGoogle Scholar
  10. 10.
    Kelsey S Problems and strategies for statistical analysis of angiographic data: Issue of changes in individual lesion versus individual patients. Workshop on the Evolution of the Human Atherosclerotic Plaque. Rockville, Maryland, September 1986.Google Scholar
  11. 11.
    Barndt R, Blankenhorn DH, Crawford DW, Brooks SH (1977) Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemia patients. Annals of Internal Medicine 86:139–146.PubMedGoogle Scholar
  12. 12.
    Little JA, Kakis G, Feather T, Breckenridge CW (1985) Plasma high density lipoprotein triglyceride (HDL-TG) as a risk factor for ischemic vascular disease in a prospective study. Proceedings of Poster Communications, 7th International Symposium on Atherosclerosis, Melbourne October 1969.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • Anders G. Olsson
    • 1
  • Uno Erikson
  • Gunnar Helmius
  • Anders Hemmingsson
  • Ingar Holme
  • Gunnar Ruhn
  1. 1.Department of Internal MedicineUniversity HospitalLinköpingSweden

Personalised recommendations